YS Biopharma Co Ltd
NASDAQ:YS
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
YS Biopharma Co Ltd
Net Income (Common)
YS Biopharma Co Ltd
Net Income (Common) Peer Comparison
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/hkex/6160.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/hkex/1801.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/sse/603392.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/szse/300122.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/szse/300896.png)
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Y
|
YS Biopharma Co Ltd
NASDAQ:YS
|
Net Income (Common)
-ÂĄ283.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
![]() |
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-ÂĄ6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
![]() |
Innovent Biologics Inc
HKEX:1801
|
Net Income (Common)
-ÂĄ1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
![]() |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
ÂĄ1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
![]() |
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Income (Common)
ÂĄ7.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
35%
|
CAGR 10-Years
50%
|
![]() |
Imeik Technology Development Co Ltd
SZSE:300896
|
Net Income (Common)
ÂĄ1.3B
|
CAGR 3-Years
61%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
See Also
What is YS Biopharma Co Ltd's Net Income (Common)?
Net Income (Common)
-283.5m
CNY
Based on the financial report for Mar 31, 2023, YS Biopharma Co Ltd's Net Income (Common) amounts to -283.5m CNY.
What is YS Biopharma Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
-20%
Over the last year, the Net Income (Common) growth was -20%.